Dolinnov

Dolinnov is a french preclinical research company dedicated to advancing solutions for chronic pain management, driven by a passion for science and innovation. Our mission is to improve patients’ lives by delivering cutting-edge solutions for severe and unbearable conditions. Leveraging our proprietary conjugated L-ASO technology, we design targeted, effective, and safer therapies. This breakthrough approach directly addresses the root causes of pain through precise molecular interventions, providing hope to those enduring chemotherapy-induced pain and other challenging conditions.